ABBV

West Pharmaceutical completes the SmartDose 3.5mL sale to AbbVie, sharpening its focus on higher-growth on-body drug delivery technologies.

AbbVie's EU approval expands Tepkinly into a first-of-its-kind bispecific lymphoma combination, backed by phase III data showing strong efficacy.

Dividend Aristocrats, the S&P 500 companies that have raised payouts for 25 or more consecutive years, remain the bedrock of income portfolios heading into the second half of 2026.

TEPKINLY ® (epcoritamab) plus lenalidomide and rituximab (R 2 ) is the first and only bispecific-based therapy approved in Europe for the treatment of relapsed or refractory follicular lymphoma in the second-line setting, offering a chemotherapy-free option In the Phase 3 EPCORE ® FL-1 trial, fixed-duration TEPKINLY + R 2 achieved statistically significant improvement of progression-free survival and overall response rates compared to R 2 , with approximately three out of four patients achieving a complete response NORTH CHICAGO, Ill., July 6, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL).

ABBV's Q2 spotlight is on Skyrizi and Rinvoq as rising immunology sales aim to offset Humira's decline ahead of July 31 earnings.

JNJ and ABBV both offer solid long-term growth potential, but differences in diversification, pipeline strength and estimates may give one stock an edge.

Dividend investors entering July 2026 have a rare setup: Three of the market's most reliable income stocks all delivered beat-and-raise first-quarter reports, all hiked their payouts in the past 12 months and all three are riding meaningful momentum into the back half of the year.

AbbVie is acquiring Apogee Therapeutics for $10.9B, reinforcing its immunology franchise and addressing future patent cliffs proactively. Skyrizi and Rinvoq have already replaced Humira's revenue, with combined sales surpassing Humira's peak and continuing to grow at 20–30% post-LOE. Zumilokibart, Apogee's lead asset, offers best-in-class efficacy and dosing convenience in atopic dermatitis, with Phase 3 data expected in 2028 and approval in 2030.

ABBV surged nearly 11% in a week as acquisitions, new approvals and pipeline expansion strengthen confidence in its long-term growth strategy.

A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country's military capabilities, according to a Reuters report. The inquiry, led by Republican Representative John Moolenaar of Michigan, chair of the House Select Committee on China, focuses on whether the drugmakers conducted adequate due diligence and maintained sufficient data protection standards at trial sites in China.